Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren in Hypertensive Type 2 Diabetic Patients With Nephropathy
NCT00464776Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aliskiren in diabetic nephropathy (DN), sponsored by Novartis. Primary endpoint: Antiproteinuric effect of increasing doses of Aliskiren. Started Oct 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00464776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00464776.